論文業績（2018年）

Imano H, Kato R, Tanikawa S, Yoshimura F, Nomura A, Ijiri Y, Yamaguchi T, Izumi Y, Yoshiyama M, Hayashi T : Factor Xa inhibition by rivaroxaban attenuates cardiac remodeling due to intermittent hypoxia. J. Pharmacol. Sci. 137: 274–282 (2018)

Savitskaya A, Nishiyama A, Yamaguchi T, Tateishi Y, Ozeki Y, Nameta M, Kon T, Kaboso S A, Ohara N, Peryanova O V, Matsumoto S : C-terminal intrinsically disordered region-dependent organization of the mycobacterial genome by a histone-like protein. Sci. Rep. 8: 8197 (2018)

Inoue M, Niki M, Ozeki Y, Nagi S, Chadeka E A, Yamaguchi T, Osada-Oka M, Ono K, Oda T, Mwende F, Kaneko Y, Matsumoto M, Kaneko S, Ichinose Y, Njenga S M, Hamano S, Matsumoto S : High-density lipoprotein suppresses tumor necrosis factor alpha production by mycobacteria-infected human macrophages. Sci. Rep. 8: 6736 (2018)

Kitajima S, Lee KL, Fujioka M, Sun W, You J, Chia GS, Wanibuchi H, Tomita S, Araki M, Kato H, Poellinger L. Hypoxia-inducible factor-2 alpha up-regulates CD70 under hypoxia and enhances anchorage-independent growth and aggressiveness in cancer cells. Oncotarget. 9:19123-19135（2018）

Tsounapi P, Honda M, Dimitriadis F, Shimizu S, Shiomi T, Hikita K, Saito M, Tomita S, Sofikitis N, Takenaka A. Antioxdant treatment ameliorates the diabetes-induced dysfunction of the vas deferens in a rat model. Andrologia. 50 (2018)

Kabei K, Tateishi Y, Nozaki M, Tanaka M, Shiota M, Osada-Oka M, Nishide S, Uchida J, Nakatani T, Tomita S, Miura K. Role of hypoxia-inducible factor-1 in the development of renal fibrosis in mouse obstructed kidney: Special references to HIF-1 dependent gene expression of profibrogenic molecules. J Pharmacol Sci. 136(1):31-38 (2018)

Osada-Oka M, Hirai S, Izumi Y, Misumi K, Samukawa K, Tomita S, Miura K, Minamiyama Y, Iwao H. Red ginseng extracts attenuate skin inflammation in atopic dermatitis through p70 ribosomal protein S6 kinase activation. J Pharmacol Sci. 136:9-15 (2018)

Kashiwagi S, Asano Y, Goto W, Takada K, Takahashi K, Hatano T, Tanaka S, Takashima T, Tomita S, Motomura H, Ohsawa M, Hirakawa K, Ohira M: Mesenchymal-epithelial Transition and Tumor Vascular Remodeling in Eribulin Chemotherapy for Breast Cancer. Anticancer Res. 38:401-410 (2018)

Kashiwagi S, Tsujio G, Asano Y, Goto W, Takada K, Takahashi K, Morisaki T, Fujita H, Takashima T, Tomita S, Ohsawa M, Hirakawa K and OhiraM: Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment.
J Transl Med. 16:54 (2018)

Asano Y, Kashiwagi S, Goto W, Takada K, Takahashi K, Hatano T, Takashima T, Tomita S, Motomura H, Ohsawa M, Hirakawa K and Ohira M: Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
Anticancer Res. 38:2311-2321 (2018)

Asano Y, Kashiwagi S, Goto W, Takada K, Takahashi K, Morisaki T, Fujita H, Takashima T, Tomita S, Ohsawa M, Hirakawa K, Ohira M: Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression. J Transl Med. 16:87 (2018)

Takada K, Kashiwagi S, Goto W, Asano Y, Takahashi K, Takashima T, Tomita S, Ohsawa M, Hirakawa K, Ohira M: Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer. J Transl Med. 16:86 (2018)

Iimori N, Kashiwagi S, Asano Y, Goto W, Takada K, Takahashi K, Hatano T, Takashima T, Tomita S, Motomura H, Hirakawa K, Ohira M: Clinical Significance of the Neutrophil-to-Lymphocyte Ratio in Endocrine Therapy for Stage IV Breast Cancer. In Vivo . 32:669-675 (2018)

Takada K, Kashiwagi S, Goto W, Asano Y, Takahashi K, Morisaki T, Takashima T, Tomita S, Hirakawa K, Ohira M: Novel evaluation scale for QOL (QOL-ACD-BP) in preoperative chemotherapy for breast cancer. J Cancer Res Clin Oncol. 144(8):1547-1559(2018)

Takada K, Kashiwagi S, Goto W, Asano Y, Takahashi K, Hatano T, Takashima T, Tomita S, Motomura H, Ohsawa M, Hirakawa K, Ohira M: Significance of re-biopsy for recurrent breast cancer in the immune tumour microenvironment. Br J Cancer. 119(5):572-579 (2018)

Goto W, Kashiwagi S, Asano Y, Takada K, Takahashi K, Hatano T, Takashima T, Tomita S, Motomura H, Ohsawa M, Hirakawa K, Ohira M: Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy. ESMO Open. 3(6):e000305(2018)

学会・研究会発表（2018年）

ISN Frontiers 2018, Feb.22-25, Tokyo

The role of HIF-1 in the development of renal fibrosis with special referenceto HIF-1 dependent gene expression.
Kabei K, Nozaki M, Uchida J, Nakatani T, Tomita S,Miura K.

18th World Congress of Basic and Clinical Pharmacology, July 1-6, Kyoto

Prolyl Hydroxylase inhibitor repaired chemo-sensitivity through tumor blood vessel normalization in tumor mouse model.
Shinji Matsunaga, Shunji Nishide, Masayuki Shiota, Takehiro Yamaghchi, Shojiro Kitajima, Katsuyuki Miura and Shuhei Tomita.

Dipeptidyl Peptidase-4 (DPP-4) inhibition Attenuates Cardiac Dysfunction after Myocardial Infarction Independently of DPP-4.
Yamaguchi T, Izumi Y, Shiota M, Tanaka M, Osada-Oka M, Matsunaga S, Kitajima S, Miura K, Iwao H, Tomita S.

Hypoxia-inducible factor-1α regulates energy fuel metabolism and mediates metabolic plasticity during ammonia stress response in ovarian cancer stem-like cells.
Shojiro Kitajima, Kian Leong Lee, Hiroki Hikasa, Shinji Matsunaga, Takehiro Yamaguchi,Shuhei Tomita, Marito Araki, Hiroyuki Kato and Lorenz Poellinger.

The role of HIF-1 in the development of renal fibrosis in mouse UUO model with special reference to HIF-1 dependent gene expression.
Kabei K, Osada-Oka M, Nozaki M, Shiota M, Tanaka M, Tomita S, Miura K.

27th International Congress of the Transplantation Society, June 30-July 5, Madrid

The new role of HIF-1 in the development of renal fibrosis in mouse UUO model
Kabei K, Uchida J, Tateishi Y, Nishide S, Kosoku A, Iwai T, Kuwabara N, Nakatani T, Miura K.